PMID- 24103632
OWN - NLM
STAT- MEDLINE
DCOM- 20140826
LR  - 20180816
IS  - 1469-5111 (Electronic)
IS  - 1461-1457 (Linking)
VI  - 17
IP  - 2
DP  - 2014 Feb
TI  - Genotype variant associated with add-on memantine in bipolar II disorder.
PG  - 189-97
LID - 10.1017/S1461145713000825 [doi]
AB  - Memantine is a non-competitive N-methyl-d-asparate (NMDA) receptor antagonist 
      with a mood-stabilizing effect. We investigated whether using valproic acid (VPA) 
      plus add-on memantine to treat bipolar II disorder (BP-II) is more effective than 
      using VPA alone (VPA + Pbo). We also evaluated, in BP-II patients, the 
      association between the brain-derived neurotrophic factor (BDNF) Val66Met 
      polymorphism with treatment response to VPA + add-on memantine and to VPA + Pbo. 
      In this randomized, double-blind, controlled 12 wk study, BP-II patients 
      undergoing regular VPA treatments were randomly assigned to a group: 
      VPA + Memantine (5 mg/day) (n = 115) or VPA + Pbo (n = 117). The Hamilton 
      Depression Rating Scale (HDRS) and Young Mania Rating Scale (YMRS) were used to 
      evaluate clinical response during week 0, 1, 2, 4, 8 and 12. The genotypes of the 
      BDNF Val66Met polymorphisms were determined using polymerase chain reactions plus 
      restriction fragment length polymorphism analysis. To adjust within-subject 
      dependence over repeated assessments, multiple linear regression with generalized 
      estimating equation methods was used to analyze the effects of the BDNF Val66Met 
      polymorphism on the clinical performance of memantine. Both groups showed 
      significantly decreased YMRS and HDRS scores after 12 wk of treatment; the 
      differences between groups were non-significant. When stratified by the BDNF 
      Val66Met genotypes, significantly greater decreases in HDRS scores were found in 
      the VPA + memantine group in patients with the Val Met genotype (p = 0.004). We 
      conclude that the BDNF Val66Met polymorphism influenced responses to add-on 
      memantine by decreasing depressive symptoms in patients with BP-II.
FAU - Lee, Sheng-Yu
AU  - Lee SY
AD  - Department of Psychiatry, National Cheng Kung University, Tainan, Taiwan.
FAU - Chen, Shiou-Lan
AU  - Chen SL
AD  - Department of Psychiatry, National Cheng Kung University, Tainan, Taiwan.
FAU - Chang, Yun-Hsuan
AU  - Chang YH
AD  - Department of Psychiatry, National Cheng Kung University, Tainan, Taiwan.
FAU - Chen, Shih-Heng
AU  - Chen SH
AD  - Department of Psychiatry, National Cheng Kung University, Tainan, Taiwan.
FAU - Chu, Chun-Hsieh
AU  - Chu CH
AD  - Department of Psychiatry, National Cheng Kung University, Tainan, Taiwan.
FAU - Huang, San-Yuan
AU  - Huang SY
AD  - Department of Psychiatry, Tri-Service General Hospital, National Defence Medical 
      Centre, Taipei, Taiwan.
FAU - Tzeng, Nian-Sheng
AU  - Tzeng NS
AD  - Department of Psychiatry, Tri-Service General Hospital, National Defence Medical 
      Centre, Taipei, Taiwan.
FAU - Wang, Chen-Lin
AU  - Wang CL
AD  - Department of Psychiatry, National Cheng Kung University, Tainan, Taiwan.
FAU - Wang, Liang-Jen
AU  - Wang LJ
AD  - Department of Child and Adolescent Psychiatry, Kaohsiung Chang Gung Memorial 
      Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.
FAU - Lee, I Hui
AU  - Lee IH
AD  - Department of Psychiatry, National Cheng Kung University, Tainan, Taiwan.
FAU - Yeh, Tzung Lieh
AU  - Yeh TL
AD  - Department of Psychiatry, National Cheng Kung University, Tainan, Taiwan.
FAU - Yang, Yen Kuang
AU  - Yang YK
AD  - Institute of Behavioural Medicine, National Cheng Kung University, Tainan, 
      Taiwan.
FAU - Hong, Jau-Shyong
AU  - Hong JS
AD  - Department of Psychiatry, National Cheng Kung University, Tainan, Taiwan.
FAU - Lu, Ru-Band
AU  - Lu RB
AD  - Department of Psychiatry, National Cheng Kung University, Tainan, Taiwan.
LA  - eng
SI  - ClinicalTrials.gov/NCT01188148
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20131009
PL  - England
TA  - Int J Neuropsychopharmacol
JT  - The international journal of neuropsychopharmacology
JID - 9815893
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 614OI1Z5WI (Valproic Acid)
RN  - 7171WSG8A2 (BDNF protein, human)
RN  - W8O17SJF3T (Memantine)
SB  - IM
EIN - Int J Neuropsychopharmacol. 2014 Jun;17(6):979. Lu, Ru-Band [removed]; Hong, 
      Jau-Shyong [added]
MH  - Adult
MH  - Bipolar Disorder/diagnosis/*drug therapy/*genetics
MH  - Brain-Derived Neurotrophic Factor/*genetics
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Female
MH  - Genetic Variation/*genetics
MH  - Humans
MH  - Male
MH  - Memantine/*administration & dosage
MH  - Polymorphism, Genetic/genetics
MH  - Valproic Acid/*administration & dosage
MH  - Young Adult
EDAT- 2013/10/10 06:00
MHDA- 2014/08/27 06:00
CRDT- 2013/10/10 06:00
PHST- 2013/10/10 06:00 [entrez]
PHST- 2013/10/10 06:00 [pubmed]
PHST- 2014/08/27 06:00 [medline]
AID - S1461145713000825 [pii]
AID - 10.1017/S1461145713000825 [doi]
PST - ppublish
SO  - Int J Neuropsychopharmacol. 2014 Feb;17(2):189-97. doi: 
      10.1017/S1461145713000825. Epub 2013 Oct 9.